Whitehawk Therapeutics (WHWK) Accumulated Expenses (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Accumulated Expenses of $759000.0 for Q1 2026, down 91.19% year-over-year from $8.6 million in Q1 2025, and down 94.42% on a QoQ basis from $13.6 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 17 years of Accumulated Expenses data on file, last reported at $759000.0 in Q1 2026.
- Quarterly Accumulated Expenses fell 91.19% year-over-year to $759000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $759000.0 (down 91.19% YoY) and the FY2025 annual result came in at $13.6 million, up 407.35% from the prior year.
- Accumulated Expenses fell to $759000.0 in Q1 2026 per WHWK's latest filing, from $13.6 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $14.9 million in Q4 2022 and bottomed at $373000.0 in Q3 2025.
- The 5-year median for Accumulated Expenses is $10.6 million (2024), against an average of $9.2 million.
- The widest annual swing landed in 2022, when Accumulated Expenses soared 1176.46%; it then slumped 97.36% in 2025.
- Tracing WHWK's Accumulated Expenses over 5 years: stood at $14.9 million in 2022, then decreased by 4.13% to $14.3 million in 2023, then sank by 81.26% to $2.7 million in 2024, then jumped by 407.35% to $13.6 million in 2025, then plunged by 94.42% to $759000.0 in 2026.
- Per Business Quant, the three latest WHWK Accumulated Expenses figures stand at $759000.0 (Q1 2026), $13.6 million (Q4 2025), and $373000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 759,000.00 |
| Dec 31, 2025 | 13.60 Mn |
| Sep 30, 2025 | 373,000.00 |
| Jun 30, 2025 | 1.18 Mn |
| Mar 31, 2025 | 8.62 Mn |
| Dec 31, 2024 | 2.68 Mn |
| Sep 30, 2024 | 14.12 Mn |
| Jun 30, 2024 | 13.75 Mn |
| Mar 31, 2024 | 10.60 Mn |
| Dec 31, 2023 | 14.31 Mn |
| Sep 30, 2023 | 11.73 Mn |
| Jun 30, 2023 | 9.69 Mn |
| Mar 31, 2023 | 10.83 Mn |
| Dec 31, 2022 | 14.92 Mn |
| Sep 30, 2022 | 13.60 Mn |
| Jun 30, 2022 | 8.65 Mn |
| Mar 31, 2022 | 7.34 Mn |
| Dec 31, 2021 | 8.70 Mn |
| Sep 30, 2021 | 6.25 Mn |
| Jun 30, 2021 | 677,891.00 |
| Mar 31, 2021 | 1.11 Mn |
| Dec 31, 2020 | 4.10 Mn |
| Sep 30, 2020 | 38,114.00 |
| Jun 30, 2020 | 318,591.00 |
| Mar 31, 2020 | 106,159.00 |
| Dec 31, 2019 | 793,913.00 |
| Sep 30, 2019 | 139,000.00 |
| Jun 30, 2019 | 591,827.00 |
| Mar 31, 2019 | 126,096.00 |
| Dec 31, 2018 | 90,663.00 |
| Sep 30, 2018 | 228,048.00 |
| Jun 30, 2018 | 136,189.00 |
| Mar 31, 2018 | 1.05 Mn |
| Dec 31, 2017 | 833,650.00 |
| Sep 30, 2017 | 470,362.00 |
| Jun 30, 2017 | 256,889.00 |
| Mar 31, 2017 | 125,576.00 |
| Sep 30, 2016 | 39,807.00 |
| Jun 30, 2016 | 3,200.00 |
| Mar 31, 2016 | 34,830.00 |
| Dec 31, 2015 | 32,436.00 |
| Sep 30, 2015 | 30,217.00 |
| Jun 30, 2015 | 3,200.00 |
| Mar 31, 2015 | 25,855.00 |
| Dec 31, 2014 | 24,002.00 |
| Sep 30, 2014 | 3,463.00 |
| Jun 30, 2014 | 20,448.00 |
| Mar 31, 2014 | 18,803.00 |
| Dec 31, 2013 | 5,500.00 |
| Sep 30, 2013 | 15,512.00 |
| Jun 30, 2013 | 13,848.00 |
| Mar 31, 2013 | 12,555.00 |
| Dec 31, 2012 | 11,298.00 |
| Sep 30, 2012 | 10,012.00 |
| Jun 30, 2012 | 8,727.00 |
| Mar 31, 2012 | 1,500.00 |
| Dec 31, 2011 | 5,500.00 |
| Sep 30, 2011 | 7,180.00 |
| Jun 30, 2011 | 6,185.00 |
| Dec 31, 2010 | 2,724.00 |